LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: The changing landscape of research funding

    Nick Wong

    Genome Biology, Vol 20, Iss 1, Pp 1-

    challenges for mid-career researchers

    2019  Volume 2

    Abstract: ... of securing funding can be improved. In this part, Nick Wong shares his experience in securing funding ...

    Abstract Abstract Funding research is a challenge faced by most scientists around the world. Genome Biology has invited four scientists based in three different countries to share their own experience and opinions regarding funding, the difficulties young scientists must overcome, and how the process of securing funding can be improved. In this part, Nick Wong shares his experience in securing funding for his research in Australia.
    Keywords Biology (General) ; QH301-705.5 ; Genetics ; QH426-470
    Language English
    Publishing date 2019-08-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Targeted Sequencing Approach and Its Clinical Applications for the Molecular Diagnosis of Human Diseases

    Xiao Meng Pei / Martin Ho Yin Yeung / Alex Ngai Nick Wong / Hin Fung Tsang / Allen Chi Shing Yu / Aldrin Kay Yuen Yim / Sze Chuen Cesar Wong

    Cells, Vol 12, Iss 493, p

    2023  Volume 493

    Abstract: The outbreak of COVID-19 has positively impacted the NGS market recently. Targeted sequencing (TS) has become an important routine technique in both clinical and research settings, with advantages including high confidence and accuracy, a reasonable ... ...

    Abstract The outbreak of COVID-19 has positively impacted the NGS market recently. Targeted sequencing (TS) has become an important routine technique in both clinical and research settings, with advantages including high confidence and accuracy, a reasonable turnaround time, relatively low cost, and fewer data burdens with the level of bioinformatics or computational demand. Since there are no clear consensus guidelines on the wide range of next-generation sequencing (NGS) platforms and techniques, there is a vital need for researchers and clinicians to develop efficient approaches, especially for the molecular diagnosis of diseases in the emergency of the disease and the global pandemic outbreak of COVID-19. In this review, we aim to summarize different methods of TS, demonstrate parameters for TS assay designs, illustrate different TS panels, discuss their limitations, and present the challenges of TS concerning their clinical application for the molecular diagnosis of human diseases.
    Keywords molecular diagnosis ; targeted sequencing ; next-generation sequencing ; COVID-19 detection ; bacteria identification ; cancer marker detection ; Biology (General) ; QH301-705.5
    Subject code 610
    Language English
    Publishing date 2023-02-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Corticosteroid injections during the COVID-19 pandemic

    David McKean / Siok Li Chung / Rory Fairhead / Oliver Bannister / Malgorzata Magliano / Joseph Papanikitas / Nick Wong / Richard Hughes

    Bone & Joint Open, Vol 1, Iss 9, Pp 605-

    experience from a UK centre

    2020  Volume 611

    Abstract: Aims: To describe the incidence of adverse clinical outcomes related to COVID-19 infection following corticosteroid injections (CSI) during the COVID-19 pandemic. To describe the incidence of positive SARS-CoV-2 reverse transcriptase polymerase chain ... ...

    Abstract Aims: To describe the incidence of adverse clinical outcomes related to COVID-19 infection following corticosteroid injections (CSI) during the COVID-19 pandemic. To describe the incidence of positive SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) testing, positive SARS-COV2 IgG antibody testing or positive imaging findings following CSI at our institution during the COVID-19 pandemic. Methods: A retrospective observational study was undertaken of consecutive patients who had CSI in our local hospitals between 1 February and 30June 2020. Electronic patient medical records (EPR) and radiology information system (RIS) database were reviewed. SARS-CoV-2 RT-PCR testing, SARS-COV2 IgG antibody testing, radiological investigations, patient management, and clinical outcomes were recorded. Lung findings were categorized according to the British Society of Thoracic Imaging (BSTI) guidelines. Reference was made to the incidence of lab-confirmed COVID-19 cases in our region. Results: Overall, 1,656 lab-confirmed COVID-19 cases were identified in our upper tier local authority (UTLA), a rate of 306.6 per 100,000, as of 30June 2020. A total of 504 CSI injections were performed on 443 patients between 1 February and 30June 2020. A total of 11 RT-PCR tests were performed on nine patients (2% of those who had CSI), all of which were negative for SARS-CoV-2 RNA, and five patients (1.1%) received an SARS-CoV-2 IgG antibody test, of which 2 (0.5%) were positive consistent with prior COVID-19 infection, however both patients were asymptomatic. Seven patients (1.6%) had radiological investigations for respiratory symptoms. One patient with indeterminate ground glass change was identified. Conclusion: The incidence of positive COVID-19 infection following corticosteroid injections was very low in our cohort and no adverse clinical outcomes related to COVID-19 infection following CSI were identified. Our findings are consistent with CSI likely being low risk during the COVID-19 pandemic. The results of this small observational study are supportive of the current multi-society guidelines regarding the judicious use of CSI.
    Keywords covid ; corticosteroid ; injection ; joint ; Orthopedic surgery ; RD701-811 ; covid19
    Subject code 610 ; 616
    Language English
    Publishing date 2020-09-01T00:00:00Z
    Publisher The British Editorial Society of Bone & Joint Surgery
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity.

    Jueqiong Wang / Carlos Farkas / Aissa Benyoucef / Catherine Carmichael / Katharina Haigh / Nick Wong / Danny Huylebroeck / Marc P Stemmler / Simone Brabletz / Thomas Brabletz / Christian M Nefzger / Steven Goossens / Geert Berx / Jose M Polo / Jody J Haigh

    PLoS Biology, Vol 19, Iss 9, p e

    2021  Volume 3001394

    Abstract: The ZEB2 transcription factor has been demonstrated to play important roles in hematopoiesis and leukemic transformation. ZEB1 is a close family member of ZEB2 but has remained more enigmatic concerning its roles in hematopoiesis. Here, we show using ... ...

    Abstract The ZEB2 transcription factor has been demonstrated to play important roles in hematopoiesis and leukemic transformation. ZEB1 is a close family member of ZEB2 but has remained more enigmatic concerning its roles in hematopoiesis. Here, we show using conditional loss-of-function approaches and bone marrow (BM) reconstitution experiments that ZEB1 plays a cell-autonomous role in hematopoietic lineage differentiation, particularly as a positive regulator of monocyte development in addition to its previously reported important role in T-cell differentiation. Analysis of existing single-cell (sc) RNA sequencing (RNA-seq) data of early hematopoiesis has revealed distinctive expression differences between Zeb1 and Zeb2 in hematopoietic stem and progenitor cell (HSPC) differentiation, with Zeb2 being more highly and broadly expressed than Zeb1 except at a key transition point (short-term HSC [ST-HSC]➔MPP1), whereby Zeb1 appears to be the dominantly expressed family member. Inducible genetic inactivation of both Zeb1 and Zeb2 using a tamoxifen-inducible Cre-mediated approach leads to acute BM failure at this transition point with increased long-term and short-term hematopoietic stem cell numbers and an accompanying decrease in all hematopoietic lineage differentiation. Bioinformatics analysis of RNA-seq data has revealed that ZEB2 acts predominantly as a transcriptional repressor involved in restraining mature hematopoietic lineage gene expression programs from being expressed too early in HSPCs. ZEB1 appears to fine-tune this repressive role during hematopoiesis to ensure hematopoietic lineage fidelity. Analysis of Rosa26 locus-based transgenic models has revealed that Zeb1 as well as Zeb2 cDNA-based overexpression within the hematopoietic system can drive extramedullary hematopoiesis/splenomegaly and enhance monocyte development. Finally, inactivation of Zeb2 alone or Zeb1/2 together was found to enhance survival in secondary MLL-AF9 acute myeloid leukemia (AML) models attesting to the oncogenic role of ZEB1/2 in AML.
    Keywords Biology (General) ; QH301-705.5
    Subject code 571
    Language English
    Publishing date 2021-09-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohortResearch in context

    Peter D. Kirwan / Victoria J. Hall / Sarah Foulkes / Ashley D. Otter / Katie Munro / Dominic Sparkes / Anna Howells / Naomi Platt / Jonathan Broad / David Crossman / Chris Norman / Diane Corrigan / Christopher H. Jackson / Michelle Cole / Colin S. Brown / Ana Atti / Jasmin Islam / Anne M. Presanis / Andre Charlett /
    Daniela De Angelis / Susan Hopkins / Tracy Lewis / Steve Bain / Rebeccah Thomas / John Geen / Carla Pothecary / Sean Cutler / John Northfield / Cathy Price / Johanne Tomlinson / Sarah Knight / Emily Macnaughton / Ekaterina Watson / Rajeka Lazarus / Aaran Sinclair / Joanne Galliford / Bridgett Masunda / Tabitha Mahungu / Alison Rodger / Esther Hanison / Simon Warren / Swati Jain / Mariyam Mirfenderesky / Natasha Mahabir / Rowan Pritchard-Jones / Diane Wycherley / Claire Gabriel / Elijah Matovu / Philippa Bakker / Simantee Guha / S. Gormley / James Pethick / Georgina Butt / Stacey Pepper / Luke Bedford / Paul Ridley / Jane Democratis / Manjula Meda / Anu Chawla / Fran Westwell / Nagesh Kalakonda / Sheena Khanduri / Allison Doel / Sumita Pai / Christian Hacon / Davis Nwaka / Veronica Mendez Moro / A. Moody / Cressida Auckland / Stephanie Prince / Thushan de Silva / Helen Shulver / A. Shah / C. Jones / Banerjee Subhro-Osuji / Angela Houston / Tim Planche / Martin Booth / Christopher Duff / Jonnie Aeron-Thomas / Ray Chaudhuri / David Hilton / Hannah Jory / Zehra'a Al-Khafaji / Philippa Kemsley / Ruth Longfellow / David Boss / Simon Brake / Louise Coke / Ngozi Elumogo / Scott Latham / Chinari Subudhi / Ina Hoad / Claire Thomas / Nihil Chitalia / Tracy Edmunds / Helen Ashby / John Elliott / Beverley Wilkinson / Abby Rand / Catherine Thompson / K. Agwuh / Anna Grice / Kelly Moran / Vijayendra Waykar / Yvonne Lester / Lauren Sach / Kathryn Court / Nikki White / Clair Favager / Kyra Holliday / Jayne Harwood / Brendan Payne / Karen Burns / Lynda Fothergill / Alejandro Arenas-Pinto / Abigail Severn / Kerryanne Brown / Katherine Gray / Jane Dare / Qi Zheng / Kathryn Hollinshead / Robert Shorten / Alun Roebuck / Christopher Holmes / Martin Wiselka / Barzo Faris / Liane Marsh / Clare McAdam / Lisa Ditchfield / Zaman Qazzafi / G. Boyd / N. Wong / Sarah Brand / Jack Squires / John Ashcroft / Ismaelette Del Rosario / Joanne Howard / Emma Ward / Gemma Harrison / Joely Morgan / Claire Corless / Ruth Penn / Nick Wong / Manny Bagary / Nadezda Starkova / Mandy Beekes / Mandy Carnahan / Shivani Khan / Shekoo Mackay / Keneisha Lewis / Graham Pickard / Joy Dawson / Lauren Finlayson / Euan Cameron / Anne Todd / Sebastien Fagegaltier / Sally Mavin / Alexandra Cochrane / Andrew Gibson / Sam Donaldson / Kate Templeton / Martin Malcolm / Beth Smith / Devesh Dhasmana / Susan Fowler / Antonia Ho / Michael Murphy / Claire Beith / Manish Patel / Elizabeth Boyd / Val Irvine / Alison Grant / Rebecca Temple-Purcell / Clodagh Loughrey / Elinor Hanna / Frances Johnston / Angel Boulos / Fiona Thompson / Yuri Protaschik / Susan Regan / Tracy Donaghy / Maurice O'Kane / Omolola Akinbami / Paola Barbero / Tim Brooks / Meera Chand / Ferdinando Insalata / Palak Joshi / Anne-Marie O'Connell / Mary Ramsay / Ayoub Saei / Maria Zambon / Ezra Linley / Simon Tonge / Enemona Adaji / Omoyeni Adebiyi / Nick Andrews / Joanna Conneely / Paul Conneely / Angela Dunne / Simone Dyer / Hannah Emmett / Nipunadi Hettiarachchi / Nishanthan Kapirial / Jameel Khawam / Edward Monk / Sophie Russell / Andrew Taylor-Kerr / Jean Timeyin / Silvia D'Arcangelo / Cathy Rowe / Amanda Semper / Eileen Gallagher / Robert Kyffin / Lisa Cromey / Desmond Areghan / Jennifer Bishop / Melanie Dembinsky / Laura Dobbie / Josie Evans / David Goldberg / Lynne Haahr / Annelysse Jorgenson / Ayodeji Matuluko / Laura Naismith / Desy Nuryunarsih / Alexander Olaoye / Caitlin Plank / Lesley Price / Nicole Sergenson / Sally Stewart / Andrew Telfer / Jennifer Weir / Ellen De Lacy / Yvette Ellis / Susannah Froude / Guy Stevens / Linda Tyson / Susanna Dunachie / Paul Klenerman / Chris Duncan / Rebecca Payne / Lance Turtle / Alex Richter / Thushan De Silva / Eleanor Barnes / Daniel Wootton / Oliver Galgut / Jonathan Heeney / Helen Baxendale / Javier Castillo-Olivares / Rupert Beale / Edward Carr / Wendy Barclay / Maya Moshe / Massimo Palmarini / Brian Willett / John Kenneth Baillie / Jennie Evans / Erika Aquino

    The Lancet Regional Health. Europe, Vol 36, Iss , Pp 100809- (2024)

    1481  

    Abstract: Summary: Background: The protection of fourth dose mRNA vaccination against SARS-CoV-2 is relevant to current global policy decisions regarding ongoing booster roll-out. We aimed to estimate the effect of fourth dose vaccination, prior infection, and ... ...

    Abstract Summary: Background: The protection of fourth dose mRNA vaccination against SARS-CoV-2 is relevant to current global policy decisions regarding ongoing booster roll-out. We aimed to estimate the effect of fourth dose vaccination, prior infection, and duration of PCR positivity in a highly-vaccinated and largely prior-COVID-19 infected cohort of UK healthcare workers. Methods: Participants underwent fortnightly PCR and regular antibody testing for SARS-CoV-2 and completed symptoms questionnaires. A multi-state model was used to estimate vaccine effectiveness (VE) against infection from a fourth dose compared to a waned third dose, with protection from prior infection and duration of PCR positivity jointly estimated. Findings: 1298 infections were detected among 9560 individuals under active follow-up between September 2022 and March 2023. Compared to a waned third dose, fourth dose VE was 13.1% (95% CI 0.9 to 23.8) overall; 24.0% (95% CI 8.5 to 36.8) in the first 2 months post-vaccination, reducing to 10.3% (95% CI −11.4 to 27.8) and 1.7% (95% CI −17.0 to 17.4) at 2–4 and 4–6 months, respectively. Relative to an infection >2 years ago and controlling for vaccination, 63.6% (95% CI 46.9 to 75.0) and 29.1% (95% CI 3.8 to 43.1) greater protection against infection was estimated for an infection within the past 0–6, and 6–12 months, respectively. A fourth dose was associated with greater protection against asymptomatic infection than symptomatic infection, whilst prior infection independently provided more protection against symptomatic infection, particularly if the infection had occurred within the previous 6 months. Duration of PCR positivity was significantly lower for asymptomatic compared to symptomatic infection. Interpretation: Despite rapid waning of protection, vaccine boosters remain an important tool in responding to the dynamic COVID-19 landscape; boosting population immunity in advance of periods of anticipated pressure, such as surging infection rates or emerging variants of concern. Funding: UK ...
    Keywords SARS-CoV-2 ; Vaccine effectiveness ; Asymptomatic ; Symptomatic ; Healthcare worker ; Cohort study ; Public aspects of medicine ; RA1-1270
    Language English
    Publishing date 2024-01-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top